812 related articles for article (PubMed ID: 19622007)
1. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
[TBL] [Abstract][Full Text] [Related]
2. Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes.
Handelsman Y; Abby SL; Jin X; Donovan JM; Jones MR
Postgrad Med; 2009 Nov; 121(6):62-9. PubMed ID: 19940418
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.
Goldberg RB; Fonseca VA; Truitt KE; Jones MR
Arch Intern Med; 2008 Jul; 168(14):1531-40. PubMed ID: 18663165
[TBL] [Abstract][Full Text] [Related]
4. Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes.
Goldfine AB; Fonseca VA; Jones MR; Wang AC; Ford DM; Truitt KE
Horm Metab Res; 2010 Jan; 42(1):23-30. PubMed ID: 19862667
[TBL] [Abstract][Full Text] [Related]
5. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
Bays HE; Davidson M; Jones MR; Abby SL
Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
[TBL] [Abstract][Full Text] [Related]
6. Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus.
Levy P
Metab Syndr Relat Disord; 2010 Dec; 8 Suppl 1():S9-13. PubMed ID: 20946010
[TBL] [Abstract][Full Text] [Related]
7. The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
Brunetti L; Hermes-Desantis ER
Ann Pharmacother; 2010; 44(7-8):1196-206. PubMed ID: 20551301
[TBL] [Abstract][Full Text] [Related]
8. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
Bays H; Rhyne J; Abby S; Lai YL; Jones M
Curr Med Res Opin; 2006 Nov; 22(11):2191-200. PubMed ID: 17076980
[TBL] [Abstract][Full Text] [Related]
9. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
10. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin.
Kadhim HM; Ismail SH; Hussein KI; Bakir IH; Sahib AS; Khalaf BH; Hussain SA
J Pineal Res; 2006 Sep; 41(2):189-93. PubMed ID: 16879326
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of colesevelam in type 2 diabetes mellitus.
Brunetti L; Campbell RK
J Pharm Pract; 2011 Aug; 24(4):417-25. PubMed ID: 21813819
[TBL] [Abstract][Full Text] [Related]
12. Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies.
Bays HE
Endocr Pract; 2011; 17(6):933-8. PubMed ID: 21856592
[TBL] [Abstract][Full Text] [Related]
13. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.
Bays HE; Goldberg RB; Truitt KE; Jones MR
Arch Intern Med; 2008 Oct; 168(18):1975-83. PubMed ID: 18852398
[TBL] [Abstract][Full Text] [Related]
14. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
Roman G; Hancu N
Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
[TBL] [Abstract][Full Text] [Related]
15. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.
Zieve FJ; Kalin MF; Schwartz SL; Jones MR; Bailey WL
Clin Ther; 2007 Jan; 29(1):74-83. PubMed ID: 17379048
[TBL] [Abstract][Full Text] [Related]
16. Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients.
Yang J; Di F; He R; Zhu X; Wang D; Yang M; Wang Y; Yuan S; Chen J
Chin Med J (Engl); 2003 May; 116(5):785-7. PubMed ID: 12875702
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.
Knopp RH; Tsunehara C; Retzlaff BM; Fish B; Nguyen H; Anderson S; Nguyen T
Metabolism; 2006 Dec; 55(12):1697-703. PubMed ID: 17142146
[TBL] [Abstract][Full Text] [Related]
18. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.
Fonseca VA; Rosenstock J; Wang AC; Truitt KE; Jones MR
Diabetes Care; 2008 Aug; 31(8):1479-84. PubMed ID: 18458145
[TBL] [Abstract][Full Text] [Related]
19. An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
Simons WR; Hagan MA
Pharmacoeconomics; 2010; 28(9):765-80. PubMed ID: 20799756
[TBL] [Abstract][Full Text] [Related]
20. Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl.
Marrs JC
Drugs Aging; 2012 May; 29(5):e1-e12. PubMed ID: 22530704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
